Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

  • Patrícia O. Guimarães
  • , Sergio Leonardi
  • , Zhen Huang
  • , Lars Wallentin
  • , Frans Van de Werf
  • , Philip E. Aylward
  • , Claes Held
  • , Robert A. Harrington
  • , David J. Moliterno
  • , Paul W. Armstrong
  • , Harvey D. White
  • , Karen P. Alexander
  • , Renato D. Lopes
  • , Kenneth W. Mahaffey
  • , Pierluigi Tricoci

Producción científica: Article › revisión exhaustiva

12 Citas (Scopus)

Resumen

Background Type 2 myocardial infarction (MI) is characterized by an imbalance between myocardial blood supply and demand, leading to myocardial ischemia without coronary plaque rupture, but its diagnosis is challenging. Methods In the TRACER trial, patients with non–ST-segment elevation acute coronary syndromes were included. We aimed to describe provoking factors, cardiac biomarker profiles, treatment patterns, and clinical outcomes of patients with type 2 MIs. MI events during trial follow-up were adjudicated by an independent clinical events classification committee (CEC) and were classified according to the Third Universal Definition of MI. Using available source documents retrieved as part of the CEC process, we performed a retrospective chart abstraction to collect details on the type 2 MIs. Cox regression models were used to explore the association between MI type (type 1 or type 2) and cardiovascular death. Results Overall, 10.3% (n = 1327) of TRACER participants had a total of 1579 adjudicated MIs during a median follow-up of 502 days (interquartile range [IQR] 349-667). Of all MIs, 5.2% (n = 82) were CEC-adjudicated type 2 MIs, occurring in 76 patients. The incidence of type 2 MI was higher in the first month following randomization, after which the distribution became more scattered. The most frequent potential provoking factors for type 2 MIs were tachyarrhythmias (38.2%), anemia/bleeding (21.1%), hypotension/shock (14.5%), and hypertensive emergencies (11.8%). Overall, 36.3% had a troponin increase >10× the upper limit of normal. Coronary angiography was performed in 22.4% (n = 17) of patients during hospitalizations due to type 2 MIs. The hazard of cardiovascular death was numerically higher following type 2 MI (vs. no MI, adj. HR 11.82, 95% CI 5.71-24.46; P <.0001) than that of type 1 MI (vs. no MI, adj. HR 8.90, 95% CI 6.93-11.43; P <.0001). Conclusions Type 2 MIs were more prevalent in the first month after ACS, were characterized by the presence of triggers and infrequent use of an invasive strategy, and were associated with a high risk of death. Further efforts are needed to better define the role and implications of type 2 MI in both clinical practice and research.

Idioma originalEnglish
Páginas (desde-hasta)28-35
Número de páginas8
PublicaciónAmerican Heart Journal
Volumen196
DOI
EstadoPublished - feb 2018

Nota bibliográfica

Publisher Copyright:
© 2017 Elsevier Inc.

Financiación

HD White: Grants from Sanofi Aventis, Eli Lilly and Company, National Institute of Health, DalGen Products and Services; personal fees and non-financial support from AstraZeneca; grants and personal fees from Omthera Pharmaceuticals, Pfizer, Elsai Inc.; personal fees from Sirtex and Acetelion. Dr. Guimarães thanks CNPq – Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, of Ministry of Science, Technology and Innovation of Brazil for her fellowship funding.

Financiadores
DalGen Products and Services
Ministry of Science, Technology and Innovation of Brazil
National Institutes of Health (NIH)
AstraZeneca
Conselho Nacional de Desenvolvimento Científico e Tecnológico

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Huella

    Profundice en los temas de investigación de 'Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial'. En conjunto forman una huella única.

    Citar esto